Dr. Derek H. Jones, MD
Dermatology (Dermatology Physician)
9201 Sunset Blvd #602
Los Angeles, CA 90069
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1997, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CA license A62154 (first issued 1997; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Minoxidil Other prescribers in Los Angeles, CA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 40 payments worth $37,235 in total to this clinician.
| Merz North America, Inc. | $25,001 |
|---|---|
| AbbVie Inc. | $12,062 |
| Sun Pharmaceutical Industries Inc. | $40.29 |
| Novartis Pharmaceuticals Corporation | $29.62 |
| Medimetriks Pharmaceuticals, Inc. | $29.25 |
| Leo Pharma Inc. | $25.08 |
| Solta Medical, A Division of Bausch Health US, LLC | $23.69 |
| Revance Therapeutics, Inc. | $23.56 |
| Consulting Fee | $32,468 |
|---|---|
| Travel and Lodging | $3,797 |
| Food and Beverage | $970 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Oct 22, 2025 | Consulting Fee | $9,500 |
| Merz North America, Inc. Nov 12, 2025 | Consulting Fee Xeomin · Dermatology | $8,352 |
| Merz North America, Inc. Nov 12, 2025 | Consulting Fee Xeomin · Dermatology | $8,352 |
| Merz North America, Inc. Nov 12, 2025 | Consulting Fee Xeomin · Dermatology | $6,264 |
| AbbVie Inc. Sep 20, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $1,426 |
| Merz North America, Inc. Nov 12, 2025 | Travel and Lodging Xeomin · Dermatology · travel to Parsippany, NJ | $1,000 |
| Merz North America, Inc. Nov 12, 2025 | Travel and Lodging Xeomin · Dermatology · travel to Parsippany, NJ | $1,000 |
| AbbVie Inc. Sep 19, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $238 |
| AbbVie Inc. Oct 22, 2025 | Travel and Lodging travel to LOS ANGELES, CA · in-kind | $133 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $29,237 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
AbbVie Inc. · Completed · NCT06387394 - M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc. - [Trial of device that is not approved or cleared by the U.S. FDA]
Galderma Laboratories, L.P. · Withheld · NCT05461300
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.